Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY ; day:19 ; month:12 ; year:2023 ; pages:1-12
Breast cancer research and treatment ; (19.12.2023), 1-12
- Creator
-
Balmaña, Judith
Fasching, Peter Andreas
Couch, Fergus J.
Delaloge, Suzette
Labidi-Galy, Intidhar
O’Shaughnessy, Joyce
Park, Yeon Hee
Eisen, Andrea F.
You, Benoit
Bourgeois, Hughes
Gonçalves, Anthony
Kemp, Zoe
Swampillai, Angela
Jankowski, Tomasz
Sohn, Joo Hyuk
Poddubskaya, Elena
Mukhametshina, Guzel
Aksoy, Sercan
Timcheva, Constanta V.
Park-Simon, Tjoung-Won
Antón-Torres, Antonio
John, Ellie
Baria, Katherine
Gibson, Isabel
Gelmon, Karen A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-023-07165-x
- URN
-
urn:nbn:de:101:1-2024030321090852677181
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Balmaña, Judith
- Fasching, Peter Andreas
- Couch, Fergus J.
- Delaloge, Suzette
- Labidi-Galy, Intidhar
- O’Shaughnessy, Joyce
- Park, Yeon Hee
- Eisen, Andrea F.
- You, Benoit
- Bourgeois, Hughes
- Gonçalves, Anthony
- Kemp, Zoe
- Swampillai, Angela
- Jankowski, Tomasz
- Sohn, Joo Hyuk
- Poddubskaya, Elena
- Mukhametshina, Guzel
- Aksoy, Sercan
- Timcheva, Constanta V.
- Park-Simon, Tjoung-Won
- Antón-Torres, Antonio
- John, Ellie
- Baria, Katherine
- Gibson, Isabel
- Gelmon, Karen A.
- SpringerLink (Online service)
Other Objects (12)
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib
Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism
Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib
Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism
Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib
Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism